Walleye Capital LLC Revance Therapeutics, Inc. Call Options Transaction History

Walleye Capital LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$2.34 - $4.73 $43,992 - $88,924	-18,800 Reduced 27.69%	49,100 $126,000
Q1 2024 May 15, 2024	BUY	$4.65 - $9.31 $205,530 - $411,502	44,200 Added 186.5%	67,900 $334,000
Q4 2023 Feb 14, 2024	BUY	$5.81 - $11.2 $108,066 - $208,320	18,600 Added 364.71%	23,700 $208,000
Q3 2023 Nov 14, 2023	SELL	$11.47 - $25.07 $32,116 - $70,196	-2,800 Reduced 35.44%	5,100 $58,000
Q2 2023 Aug 14, 2023	BUY	$24.7 - $37.61 $59,280 - $90,264	2,400 Added 43.64%	7,900 $199,000
Q1 2023 May 15, 2023	BUY	$18.36 - $35.27 $100,980 - $193,985	5,500 New	5,500 $177,000
Q3 2019 Nov 14, 2019	SELL	$10.22 - $14.5 $286,160 - $406,000	-28,000 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$10.67 - $15.49 $298,760 - $433,720	28,000 New	28,000 $363,000

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.